{"entity":{"type":"insider","cik":"0001726334","url":"/insider/0001726334","json_url":"/insider/0001726334.json","name":"Pontifax Management 4 G.P. (2015) Ltd.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":31,"n_filings":9,"first":"2018-03-23","last":"2025-10-17","span_basis":"filed_date"},"name_variants":[{"name":"Pontifax Management 4 G.P. (2015) Ltd.","source":"filing","n_filings":9,"first_seen":"2018-03-23","last_seen":"2025-10-17"}],"transactions":[{"id":4657796,"accession":"0000921895-25-002765","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000921895-25-002765","line_url":"/filing/0000921895-25-002765","is_derivative":false,"issuer_cik":"0001568077","issuer_name":"Keros Therapeutics, Inc.","issuer_ticker":"KROS","issuer_name_source":null,"issuer_url":"/issuer/0001568077","owner_cik":null,"owner_name":"Kariv Tomer; Pontifax Late Stage Fund L.P.; Pontifax (China) IV L.P.; Nussbaum Ran; Pontifax (Israel) IV, L.P.; Pontifax Late Stage GP Ltd.; Pontifax (Cayman) IV L.P.; Pontifax Management 4 G.P. (2015) Ltd.","owner_display_name":"Kariv Tomer","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock, $0.0001 par value per share","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4787331.0,"shares_display":"4,787,331","price_per_share":17.75,"price_display":"17.75","price_state":"stated","total_value":84975125.25,"total_display":"84,975,125.25","total_whole":"84,975,125","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-10-15","filed_date":"2025-10-17","scope":"insider","n_lines":4},{"id":4037560,"accession":"0001726334-25-000003","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001726334-25-000003","line_url":"/filing/0001726334-25-000003#line-2","is_derivative":false,"issuer_cik":"0001691082","issuer_name":"LB PHARMACEUTICALS INC","issuer_ticker":"LBRX","issuer_name_source":null,"issuer_url":"/issuer/0001691082","owner_cik":"0001726334","owner_name":"Pontifax Management 4 G.P. (2015) Ltd.","owner_display_name":"Pontifax Management 4 G.P. (2015) Ltd.","owner_url":"/insider/0001726334","role":"Ten percent owner","role_mark":"%","role_mark_label":"Ten percent owner","role_mark_generic":"Ten percent owner","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000000.0,"shares_display":"1,000,000","price_per_share":15.0,"price_display":"15.00","price_state":"stated","total_value":15000000.0,"total_display":"15,000,000.00","total_whole":"15,000,000","shares_owned_after":1411681.0,"shares_owned_after_display":"1,411,681","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-09-12","filed_date":"2025-09-16","scope":"insider"},{"id":5459524,"accession":"0001104659-21-067336","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001104659-21-067336","line_url":"/filing/0001104659-21-067336","is_derivative":false,"issuer_cik":"0001035354","issuer_name":"Eloxx Pharmaceuticals, Inc.","issuer_ticker":"ELOX","issuer_name_source":null,"issuer_url":"/issuer/0001035354","owner_cik":null,"owner_name":"Pontifax IV GP L.P.; Pontifax Management 4 G.P. (2015) Ltd.; Pontifax (Israel) IV, L.P.; Pontifax (Cayman) IV L.P.; Pontifax (China) IV L.P.","owner_display_name":"Pontifax IV GP L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5925925.0,"shares_display":"5,925,925","price_per_share":1.35,"price_display":"1.35","price_state":"stated","total_value":7999998.75,"total_display":"7,999,998.75","total_whole":"7,999,999","shares_owned_after":3679797.0,"shares_owned_after_display":"3,679,797","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-05-13","filed_date":"2021-05-17","scope":"insider","n_lines":4},{"id":2049560,"accession":"0001209191-20-059404","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-20-059404","line_url":"/filing/0001209191-20-059404","is_derivative":false,"issuer_cik":"0001664710","issuer_name":"Keros Therapeutics, Inc.","issuer_ticker":"KROS","issuer_name_source":null,"issuer_url":"/issuer/0001664710","owner_cik":null,"owner_name":"Pontifax (Israel) IV, L.P.; Pontifax (Cayman) IV L.P.; Pontifax Late Stage Fund L.P.; Pontifax Late Stage GP Ltd.; Pontifax (China) IV L.P.; Pontifax Management 4 G.P. (2015) Ltd.","owner_display_name":"Pontifax (Israel) IV, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":60000.0,"shares_display":"60,000","price_per_share":50.0,"price_display":"50.00","price_state":"stated","total_value":3000000.0,"total_display":"3,000,000.00","total_whole":"3,000,000","shares_owned_after":2288151.0,"shares_owned_after_display":"2,288,151","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-11-17","filed_date":"2020-11-19","scope":"insider","n_lines":4},{"id":3008923,"accession":"0001209191-20-024231","txn_seq":15,"anchor":"line-15","filing_url":"/filing/0001209191-20-024231","line_url":"/filing/0001209191-20-024231","is_derivative":false,"issuer_cik":"0001664710","issuer_name":"Keros Therapeutics, Inc.","issuer_ticker":"KROS","issuer_name_source":null,"issuer_url":"/issuer/0001664710","owner_cik":null,"owner_name":"Pontifax Late Stage Fund L.P.; Pontifax Management 4 G.P. (2015) Ltd.; Pontifax (Israel) IV, L.P.; Pontifax (Cayman) IV L.P.; Pontifax (China) IV L.P.; Pontifax Late Stage GP Ltd.","owner_display_name":"Pontifax Late Stage Fund L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":437499.0,"shares_display":"437,499","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":6999984.0,"total_display":"6,999,984.00","total_whole":"6,999,984","shares_owned_after":2261517.0,"shares_owned_after_display":"2,261,517","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-04-13","filed_date":"2020-04-13","scope":"insider","n_lines":4},{"id":8438092,"accession":"0000899243-19-027228","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000899243-19-027228","line_url":"/filing/0000899243-19-027228#line-1","is_derivative":false,"issuer_cik":"0001568077","issuer_name":"89bio, Inc.","issuer_ticker":"ETNB","issuer_name_source":null,"issuer_url":"/issuer/0001568077","owner_cik":null,"owner_name":"Kariv Tomer; Pontifax (China) V, L.P.; Pontifax Management 4 G.P. (2015) Ltd.; Pontifax Late Stage GP Ltd.; Pontifax (Cayman) V, L.P.; Pontifax (Israel) V, L.P.; Pontifax 5 G.P. L.P.; Pontifax Late Stage Fund L.P.","owner_display_name":"Kariv Tomer","owner_url":null,"role":"Director, Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":8,"other_reporting_owners":7,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":250000.0,"shares_display":"250,000","price_per_share":16.0,"price_display":"16.00","price_state":"stated","total_value":4000000.0,"total_display":"4,000,000.00","total_whole":"4,000,000","shares_owned_after":250000.0,"shares_owned_after_display":"250,000","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-11-11","filed_date":"2019-11-13","scope":"insider"},{"id":8038373,"accession":"0001144204-19-032482","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001144204-19-032482","line_url":"/filing/0001144204-19-032482","is_derivative":false,"issuer_cik":"0001035354","issuer_name":"Eloxx Pharmaceuticals, Inc.","issuer_ticker":"ELOX","issuer_name_source":null,"issuer_url":"/issuer/0001035354","owner_cik":null,"owner_name":"Pontifax (Cayman) IV L.P.; Pontifax (Israel) IV, L.P.; Pontifax IV GP L.P.; Pontifax Management 4 G.P. (2015) Ltd.; Pontifax (China) IV L.P.","owner_display_name":"Pontifax (Cayman) IV L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":200000.0,"shares_display":"200,000","price_per_share":9.0,"price_display":"9.00","price_state":"stated","total_value":1800000.0,"total_display":"1,800,000.00","total_whole":"1,800,000","shares_owned_after":1049310.0,"shares_owned_after_display":"1,049,310","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-06-24","filed_date":"2019-06-26","scope":"insider","n_lines":4},{"id":6076245,"accession":"0001209191-18-027114","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-18-027114","line_url":"/filing/0001209191-18-027114","is_derivative":false,"issuer_cik":"0001035354","issuer_name":"Eloxx Pharmaceuticals, Inc.","issuer_ticker":"ELOX","issuer_name_source":null,"issuer_url":"/issuer/0001035354","owner_cik":null,"owner_name":"Pontifax IV GP L.P.; Pontifax (China) IV L.P.; Pontifax (Cayman) IV L.P.; Pontifax (Israel) IV, L.P.; Pontifax Management 4 G.P. (2015) Ltd.","owner_display_name":"Pontifax IV GP L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":350000.0,"shares_display":"350,000","price_per_share":9.75,"price_display":"9.75","price_state":"stated","total_value":3412500.0,"total_display":"3,412,500.00","total_whole":"3,412,500","shares_owned_after":962504.0,"shares_owned_after_display":"962,504","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-04-30","filed_date":"2018-05-01","scope":"insider","n_lines":3},{"id":6394565,"accession":"0001209191-18-021389","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-18-021389","line_url":"/filing/0001209191-18-021389","is_derivative":false,"issuer_cik":"0001035354","issuer_name":"Eloxx Pharmaceuticals, Inc.","issuer_ticker":"ELOX","issuer_name_source":null,"issuer_url":"/issuer/0001035354","owner_cik":null,"owner_name":"Pontifax (China) IV L.P.; Pontifax Management 4 G.P. (2015) Ltd.; Pontifax IV GP L.P.; Pontifax (Cayman) IV L.P.; Pontifax (Israel) IV, L.P.","owner_display_name":"Pontifax (China) IV L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6000.0,"shares_display":"6,000","price_per_share":8.0,"price_display":"8.00","price_state":"stated","total_value":48000.0,"total_display":"48,000.00","total_whole":"48,000","shares_owned_after":789878.0,"shares_owned_after_display":"789,878","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-03-22","filed_date":"2018-03-23","scope":"insider","n_lines":3},{"id":6394559,"accession":"0001209191-18-021389","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-18-021389","line_url":"/filing/0001209191-18-021389","is_derivative":false,"issuer_cik":"0001035354","issuer_name":"Eloxx Pharmaceuticals, Inc.","issuer_ticker":"ELOX","issuer_name_source":null,"issuer_url":"/issuer/0001035354","owner_cik":null,"owner_name":"Pontifax (China) IV L.P.; Pontifax Management 4 G.P. (2015) Ltd.; Pontifax IV GP L.P.; Pontifax (Cayman) IV L.P.; Pontifax (Israel) IV, L.P.","owner_display_name":"Pontifax (China) IV L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":6600.0,"shares_display":"6,600","price_per_share":7.55,"price_display":"7.55","price_state":"stated","total_value":49830.0,"total_display":"49,830.00","total_whole":"49,830","shares_owned_after":786919.0,"shares_owned_after_display":"786,919","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-03-21","filed_date":"2018-03-23","scope":"insider","n_lines":3}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":1,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":1,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":1},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001664710","name":"Keros Therapeutics, Inc.","url":"/issuer/0001664710","role":"Ten percent owner","n_filings":3,"first_seen":"2020-04-13","last_seen":"2025-10-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001691082","name":"LB PHARMACEUTICALS INC","url":"/issuer/0001691082","role":"Ten percent owner","n_filings":1,"first_seen":"2025-09-16","last_seen":"2025-09-16"},{"type":"issuer","type_label":"ISSUER","cik":"0001035354","name":"Eloxx Pharmaceuticals, Inc.","url":"/issuer/0001035354","role":"Ten percent owner","n_filings":4,"first_seen":"2018-03-23","last_seen":"2021-05-17"},{"type":"issuer","type_label":"ISSUER","cik":"0001785173","name":"89bio, Inc.","url":"/issuer/0001785173","role":"Ten percent owner","n_filings":1,"first_seen":"2019-11-13","last_seen":"2019-11-13"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001726334","retrieved_at":"2026-08-22T23:21:53+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}